TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

Filipa Lynce(Institut Claudius Regaud), Kornélia Polyák(Dana-Farber Cancer Institute), Meredith M. Regan(Dana-Farber Cancer Institute), Faina Nakhlis(Brigham and Women's Hospital), Antonio C. Wolff(Johns Hopkins University), Alastair M. Thompson(Baylor College of Medicine), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Tufia C. Haddad(Mayo Clinic), Anushree C. Gulvady(Harvard University), Ian E. Krop(Yale Cancer Center), Edward T. Richardson(Brigham and Women's Hospital), Vered Stearns(Johns Hopkins University), Amy S. Clark(Abramson Center for Jewish Life), Jeremy M. Force(Duke University), Sara M. Tolaney(Harvard University), Paulina Lange(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), E. Shelley Hwang(Duke University), Zheqi Li(Sun Yat-sen University), Tari A. King(Brigham and Women's Hospital), Beth Overmoyer(Harvard University), Ying Huang(Mianyang Third People's Hospital), Naoto T. Ueno(Breast Cancer Care), Justin M. Balko(Vanderbilt University Medical Center), Ashka Patel(Brigham and Women's Hospital), Jane E. Brock(Brigham and Women's Hospital), Jennifer R. Bellon(Brigham and Women's Hospital), Gaorav P. Gupta(University of North Carolina at Chapel Hill), Laura E. Stevens(Brigham and Women's Hospital)
Breast Cancer Research
January 31, 2024
Cited by 22


Related Papers